Breast cancer treatment with PARP inhibitors, efficacy and future of research
A new review from Italian researchers summarizes evidence of efficacy of PARP inhibitors, focusing on potential new applications and the future of clinical research with these agents
Effects of neoadjuvant-adjuvant pertuzumab in HER2- positive early breast cancer
The final analysis of phase III PEONY trial confirms a positive benefit/risk ratio of neoadjuvant/adjuvant pertuzumab, trastuzumab, and docetaxel treatment in patients with HER2+ early breast cancer
Ribociclib plus hormone therapy improves outcomes in early stage HR+/HER2- breast cancer
Results from the NATALEE trial show disease-free survival benefits with ribociclib added to aromatase inhibitors compared to hormone therapy alone
Inavosilib in HR+/HER2- locally advanced or metastatic breast cancer
INAVO120 trial primary analysis shows benefits with inavosilib added to palbociclib and fulvestrant in PIK3CA-mutant locally advanced or metastatic breast cancer
New data from APTneo Michelangelo trial presented during San Antonio Breast Cancer Symposium
Higher pathologic complete response rate with atezolizumab added to anthracycline and cyclophosphamide and chemotherapy plus trastuzumab/pertuzumab in HER2+ breast cancer
Patritumab deruxtecan in HER-3 expressing metastatic breast cancer
A phase I/II trial shows that this HER3-targeted antibody-drug conjugate has a manageable safety profile and durable efficacy in heavily pretreated patients across clinical subtypes
Oral SERDs in ER+/HER2- metastatic breast cancer, an analysis of ESR1 wild type/mutant subgroups
An individual patient data metanalysis suggests that oral SERDs improve progression-free survival in ESR1 mutant subgroup, with no significant benefit in ESR1 wild type patients
Molecular features of high proliferation/low ER-related signaling breast cancers suggest more effective therapeutic strategies
A study from Michelangelo Foundation researchers in collaboration with San Raffaele Hospital offers new insights for the treatment of high proliferation/low ER-signaling breast cancers based on molecular features
New data from Michelangelo Foundation’s NeoTRIP trial discussed during ESMO Congress
No Event-free survival improvement by addition of atezolizumab to neoadjuvant chemotherapy in NeoTRIP study but in a subset of triple negative breast cancer with a newly identified predictor restricted to benefit from the anti-PD-L1 antibody
Sacituzumab govitecan in ER+/HER2- metastatic breast cancer
The phase 3 trial TROPiCS-02 shows that the antibody-drug conjugate is safe and effective in heavily treated metastatic breast cancer with limited treatment options